These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12562445)

  • 1. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
    Lauritsen K; Devière J; Bigard MA; Bayerdörffer E; Mózsik G; Murray F; Kristjánsdóttir S; Savarino V; Vetvik K; De Freitas D; Orive V; Rodrigo L; Fried M; Morris J; Schneider H; Eklund S; Larkö A;
    Aliment Pharmacol Ther; 2003 Feb; 17(3):333-41. PubMed ID: 12562445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
    Lauritsen K; Devière J; Bigard MA; Bayerdörffer E; Mózsik G; Murray F; Kristjánsdóttir S; Savarino V; Vetvik K; De Freitas D; Orive V; Rodrigo L; Fried M; Morris J; Schneider H; Eklund S; Larkö A
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():24; discussion 25-7. PubMed ID: 12614304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
    Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis.
    Vakil N
    Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():21-3. PubMed ID: 12614303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
    Goh KL; Benamouzig R; Sander P; Schwan T;
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):205-11. PubMed ID: 17301646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esomeprazole: a review of its use in the management of acid-related disorders.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis.
    Sjöstedt S; Befrits R; Sylvan A; Harthon C; Jörgensen L; Carling L; Modin S; Stubberöd A; Toth E; Lind T
    Aliment Pharmacol Ther; 2005 Aug; 22(3):183-91. PubMed ID: 16091055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
    Moraes-Filho JP; Pedroso M; Quigley EM;
    Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
    Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
    Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
    Mee AS; Rowley JL
    Aliment Pharmacol Ther; 1996 Oct; 10(5):757-63. PubMed ID: 8899084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
    Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
    Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
    Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Eklund S;
    Aliment Pharmacol Ther; 2005 Mar; 21(6):739-46. PubMed ID: 15771760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
    Fennerty MB; Johanson JF; Hwang C; Sostek M
    Aliment Pharmacol Ther; 2005 Feb; 21(4):455-63. PubMed ID: 15709997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
    Vakil NB; Shaker R; Johnson DA; Kovacs T; Baerg RD; Hwang C; D'Amico D; Hamelin B
    Aliment Pharmacol Ther; 2001 Jul; 15(7):927-35. PubMed ID: 11421866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis.
    Hatlebakk JG; Berstad A
    Aliment Pharmacol Ther; 1997 Apr; 11(2):365-72. PubMed ID: 9146777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
    Croxtall JD; Scott LJ
    Drugs; 2010 Aug; 70(12):1593-601. PubMed ID: 20687622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study.
    Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
    Aliment Pharmacol Ther; 2009 Jun; 29(11):1165-71. PubMed ID: 19298581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis.
    Raghunath AS; Green JR; Edwards SJ
    Clin Ther; 2003 Jul; 25(7):2088-101. PubMed ID: 12946553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole.
    Hatlebakk JG; Berstad A
    Aliment Pharmacol Ther; 1997 Dec; 11(6):1093-9. PubMed ID: 9663835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.